CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case-control study.
Pharmacogenet Genomics 2016;
26:66-73. [PMID:
26544900 PMCID:
PMC4704657 DOI:
10.1097/fpc.0000000000000186]
[Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
The aim of this study was to assess whether the CYP2C9*2 and/or *3 variants might modify the risk for NSAID-related upper gastrointestinal bleeding (UGIB) in NSAID users.
Collapse